|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 亚太地区胃食管反流病的处理共识:更新版显示文摘背景与目的:自从2004年亚太地区胃食管反流病(GERD)共识发表以来,更多关于GERD流行病学和处理的文献资料相继出现。有必要对这些资料进行循证综述,对共识作出更新。方法:由多学科专家组应用德尔菲(Delphi)法制定共识条文,提呈相关资料,并对证据质量、推荐力度和共识水平进行分级。结果:亚洲GERD发生率日益增加。其危险因素包括老年、男性、种族、家族史、社会经济地位高、体重指数增加和吸烟。对于有典型症状而无报警症状的患者,对质子泵抑制剂(PPI)试验有症状应答具有诊断意义。如PPI试验失败,停止治疗后pH监测结果阴性可排除GERD。窄带成像、胶囊内镜检查和无线pH监测的作用尚未明确。亚洲诊断策略的制定须考虑到并存的胃癌和消化性溃疡。减轻体质量和抬高床头可改善反流症状。PPIs是最有效的内科治疗手段。对于非糜烂性反流病(NERD)患者,按需治疗较为适宜。有慢性咳嗽、喉炎和典型GERD症状的患者在排除非GERD病因后,应予PPI每天两次治疗。如有经验丰富的外科医师,GERD患者可行胃底折叠术。除临床试验外,GERD不应采用内镜治疗。结论:新的诊断方法和内镜治疗的作用有待进一步研究阐明。亚洲GERD诊断策略的制定须考虑到并存的胃癌和消化性溃疡。PPIs仍为治疗的基石。 | Kwong Ming Fock Nicholas J Talley Ronnie Fass Khean Lee Goh Peter Katelaris Richard Hunt Michio Hongo Tiing Leong Ang Gerald Holtmann Sanjay Nandurkar San Ren Lin Benjamin CY Wong Francis KL Chan Abdul Aziz Rani Young-Tae Bak Jose Sollano Khek Yu Ho Sathoporn Manatsathit 钱本余 | 2008 | 胃肠病学2008，13，7： | 21 |
| 2 | APASL consensus statements and management algorithms for hepatitis C virus infection显示文摘 | Masao Omata Tatsuo Kanda Ming-Lung Yu Osamu Yokosuka Seng-Gee Lim Wasim Jafri Ryosuke Tateishi Saeed S. Hamid Wan-Long Chuang Anuchit Chutaputti Lai Wei Jose Sollano Shiv Kumar Sarin Jia-Horng Kao Geoffrey W. McCaughan | 2012 | Hepatology International2012，，2： | 8 |
| 3 | Screening for gastric cancer in Asia: current evidence and practice显示文摘 | Wai K Leung Ming-shiang Wu Yasuo Kakugawa Jae J Kim Khay-guan Yeoh Khean Lee Goh Kai-chun Wu Deng-chyang Wu Jose Sollano Udom Kachintorn Takuji Gotoda Jaw-town Lin Wei-cheng You Enders KW Ng Joseph JY Sung | 2008 | Lancet Oncology2008，，3： | 7 |
| 4 | APASL consensus statements and management algorithms for hepatitis C virus infection显示文摘 | Masao Omata Tatsuo Kanda Ming-Lung Yu Osamu Yokosuka Seng-Gee Lim Wasim Jafri Ryosuke Tateishi Saeed S. Hamid Wan-Long Chuang Anuchit Chutaputti Lai Wei Jose Sollano Shiv Kumar Sarin Jia-Horng Kao Geoffrey W. McCaughan | 2012 | Hepatology International2012，，2： | 3 |
| 5 | Screening for gastric cancer in Asia: current evidence and practice显示文摘 | Wai K Leung Ming-shiang Wu Yasuo Kakugawa Jae J Kim Khay-guan Yeoh Khean Lee Goh Kai-chun Wu Deng-chyang Wu Jose Sollano Udom Kachintorn Takuji Gotoda Jaw-town Lin Wei-cheng You Enders KW Ng Joseph JY Sung | 2008 | Lancet Oncology2008，，3： | 3 |
| 6 | Hepatitis B infection among adults in the philippines:A national seroprevalence study显示文摘AIM:To determine the prevalence of hepatitis B surface antigen(HBsAg)seropositivity among adult Filipinos.METHODS:Testing for HBsAg was performed on serum samples from persons aged ≥ 20 years old who participated in the National Nutrition and Health Survey(NNHeS)conducted in 2003.Information on age,sex,marital status,educational attainment,employment status,and income were collected.For this study,marital status was classified as never married or otherwise(i.e.,married,divorced,separated,widowed);educational attainment was classified as high school graduate or below or at least some tertiary education;and employment status was classified as currently employed or currently unemployed.Annual income was divided into 4 quartiles in Philippine pesos(PhP):Q1,≤ PhP 53064;Q2,PhP 53065-92192;Q3,PhP 92193-173387;and Q4,≥ PhP 173388.Prevalence estimates were weighted so that they represented the general population.Social and demographic factors were correlated with HBsAg seropositivity.Multivariate analysis was used to determine independent predictors of HBsAg seropositivity.RESULTS:A total of 2150 randomly selected adults,20 years and over,out of the 4753 adult participants of NNHeS were tested for HBsAg.The HBsAg seroprevalence was 16.7%(95%CI:14.3%-19.1%),which corresponded to an estimated 7278968 persons infected with hepatitis B.There was no significant difference between males and females(17.5% vs 16.0%;P = 0.555).This corresponded to an estimated 3721775 men and 3557193 women infected with hepatitis B.The HBsAg seroprevalence peaked at age 20-39 years old,with declining prevalence in the older age groups.The only independent predictor of HBsAg seropositivity was the annual income,with persons in the highest income quartile being less likely to be HBsAg positive(age-adjusted OR = 0.51;95%CI:0.30-0.86)compared to subjects in the lowest income quartile.Sex,marital status,educational attainment,and employment status were not found to be independent predictors of HBsAg seropositivity.CONCLUSION:The high HBsAg seroprevalence among adults in the Philippines classifies the country as hyperendemic for HBV infection and appears unchanged over the last few decades. | Stephen N Wong Janus P Ong Madalinee Eternity D Labio Oscar T Cabahug Maria Lourdes O Daez Erlinda V Valdellon Jose D Sollano Jr Marilyn O Arguillas | 2013 | World Journal of Hepatology2013，5，4： | 3 |
| 7 | Colorectal neoplasm in asymptomatic Asians: a prospective multinational multicenter colonoscopy survey显示文摘 | Jeong-Sik Byeon Suk-Kyun Yang Tae Il Kim Won Ho Kim James Y.W. Lau Wai-Keung Leung Rikiya Fujita Govind K. Makharia Murdan Abdullah Ida Hilmi Jose Sollano Khay-Guan Yeoh Deng-Chyang Wu Min Hu Chen Pradermchai Kongkam Joseph J.Y. Sung | 2007 | Gastrointestinal Endoscopy2007，，： | 2 |
| 8 | Hepatoprotective activi- ty of a phytotherapeutic formula on thioacetamide-induced liver fi- brosis model 显示文摘 | Kantah M K Kobayashi R Sollano J | 2011 | Acta Biomed2011，82，1： | 1 |
| 9 | Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B显示文摘 | SHERMAN M YURDAYDIN C SOLLANO J | 2006 | Gastroenterology2006，130，7： | 1 |
| 10 | Entecavir for treatment of lamivudine-refractory, HBeAg positive chronic hepatitis B 显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，7： | 1 |
| 11 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | SHERMAN M YURDAYDIN C SOLLANO J | 2006 | Gastroenterology2006，130，7： | 1 |
| 12 | Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B 显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，7： | 1 |
| 13 | Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B 显示文摘 | Sherman M Yardaydin C Sollano J | 2006 | Gastroenterology2006，130，7： | 1 |
| 14 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | Sherman M Yurdaydin C Sollano J | | 0，，07： | 1 |
| 15 | Prevention of hepatocellular carcinoma complicating chronic hepatitis C显示文摘 | Ueno Y Sollano JD Farrell GC | 2009 | J Gastroenterol Hepatol2009，24，4： | 1 |
| 16 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，： | 1 |
| 17 | Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory,HBeAg( + ) chronic hepatitis B :Results of phase Ⅲ study ETV- 026 显示文摘 | SHERMAN M YURDAYDIN C SOLLANO J | 2004 | Hepatology2004，40，41： | 1 |
| 18 | Entecavir is superior to continued lamivudine for the treatment of lamivudine -refractory, HBsAg + chronic hepatitis B: Results of phase Ⅲ study ETV - 026 显示文摘 | Sherman M Yurdaydin C Sollano J | 2004 | Hepatol2004，40，4： | 1 |
| 19 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，7： | 1 |
| 20 | Endoscopic hemostasis of bleeding peptic ulcers: 1:10000 adrenalin injection vs. 1:10000 adrenalin +1% aethoxysclerol injection vs. heater probe显示文摘 | Jose D. Sollano M.D. V. N. Ang J. A. Moreno | 1991 | Gastroenterologia Japonica1991，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员